These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 8712106

  • 1. Fluvastatin versus pravastatin.
    Chilton R.
    Am J Cardiol; 1996 Jul 01; 78(1):127. PubMed ID: 8712106
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B, Benghozi R, Pfister P, Holmes D.
    Am J Cardiol; 1995 Jul 13; 76(2):54A-56A. PubMed ID: 7604799
    [Abstract] [Full Text] [Related]

  • 3. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Pincus J.
    Am J Cardiol; 1998 Aug 01; 82(3):406-7. PubMed ID: 9708683
    [No Abstract] [Full Text] [Related]

  • 4. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
    Milani M, Cimminiello C, Merlo B, Lorena M, Arpaia G, Bonfardeci G.
    Am J Cardiol; 1995 Jul 13; 76(2):51A-53A. PubMed ID: 7604798
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
    Kong SX, Crawford SY, Gandhi SK, Seeger JD, Schumock GT, Lam NP, Stubbings J, Schoen MD.
    Clin Ther; 1997 Jul 13; 19(4):778-97. PubMed ID: 9377621
    [Abstract] [Full Text] [Related]

  • 6. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia.
    Inami S, Okamatsu K, Takano M, Takagi G, Sakai S, Sano J, Mizuno K.
    Jpn Heart J; 2004 Nov 13; 45(6):969-75. PubMed ID: 15655272
    [Abstract] [Full Text] [Related]

  • 7. [Drug of the month. Fluvastatin (Lescol)].
    Scheen AJ.
    Rev Med Liege; 1997 Jun 13; 52(6):442-4. PubMed ID: 9289778
    [No Abstract] [Full Text] [Related]

  • 8. Effects of 1-year treatment with fluvastatin or pravastatin on bone.
    Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T.
    Am J Med; 2001 May 13; 110(7):584-7. PubMed ID: 11343673
    [No Abstract] [Full Text] [Related]

  • 9. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P, Kafonek S, Laurora I, Hunninghake D.
    Am J Cardiol; 1998 Mar 01; 81(5):582-7. PubMed ID: 9514454
    [Abstract] [Full Text] [Related]

  • 10. Frequency of creatine kinase elevation during treatment with fluvastatin.
    Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L.
    Am J Cardiol; 2002 Jan 15; 89(2):231-3. PubMed ID: 11792351
    [No Abstract] [Full Text] [Related]

  • 11. Fluvastatin for lowering cholesterol.
    Med Lett Drugs Ther; 1994 May 27; 36(923):45-6. PubMed ID: 8177137
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P.
    Am J Cardiovasc Drugs; 2006 May 27; 6(3):177-88. PubMed ID: 16780391
    [Abstract] [Full Text] [Related]

  • 13. Effects of fluvastatin on human biliary lipids.
    Tazuma S, Ohya T, Mizuno T, Takizawa I, Kunita T, Takata K, Hayashi K, Hino F, Tokumo H, Watanabe T.
    Am J Cardiol; 1995 Jul 13; 76(2):110A-113A. PubMed ID: 7604783
    [Abstract] [Full Text] [Related]

  • 14. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A.
    Am J Cardiol; 1995 Jul 13; 76(2):62A-64A. PubMed ID: 7604801
    [Abstract] [Full Text] [Related]

  • 15. Statins and PHARMAC.
    Ellis C, McHaffie D, Elliott J, Wilkins G.
    N Z Med J; 1999 Feb 26; 112(1082):55-6. PubMed ID: 10091894
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I, Spinler SA, Johnson NE.
    Ann Pharmacother; 1995 Feb 26; 29(7-8):743-59. PubMed ID: 8520093
    [Abstract] [Full Text] [Related]

  • 18. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H, Hartmann A, Stenstrøm J, Dahl KJ, Borge M, Pfister P.
    Am J Cardiol; 1995 Jul 13; 76(2):102A-106A. PubMed ID: 7604781
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD.
    Am J Cardiol; 1995 Jul 13; 76(2):37A-40A. PubMed ID: 7604795
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May 13; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.